The news is by your side.

DBV Technologies

DBV Technologies peanut allergy drug fails key study

WASHINGTON: DBV Technologies SA said on Friday its peanut allergy treatment did not meet the main goal in a highly anticipated late-stage study, sending its U.S.-listed shares sharply down. Nasdaq-listed shares of the French drug developer plunged 60.5 percent to $19 in extended trading. The trial, which tested a 250 microgram stick-on patch called Viaskin Peanut, in 356 children between the ages of 4-11, missed the main goal of achieving a certain tolerance to peanut protein. Shares of rival Aimmune Therapeutics…